Teriflunomide Tablet, Film Coated
Product Images NDC 70377-018

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 70377-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel- 7 mg Tablet Blister (Teriflunomide 05)

Teriflunomide Tablets 7 mg film-coated oral tablets packaging label by Biocon Pharma Inc. The carton indicates 28 tablets with Rx only status. The label includes a blister pack diagram labeled with days for daily dosing and storage instructions. The NDC is 70377-017-91.*

FDA Label Image

Principal Display Panel- 7 mg Tablet Bottle (Bottle 7mg)

Label for Teriflunomide Tablets 7 mg film-coated oral tablets by Biocon Pharma Inc., containing 30 tablets per package. The label includes dosage instructions, storage conditions, a barcode, and manufacturing information indicating production in India by Biocon Pharma Limited.*

FDA Label Image

Principal Display Panel- 7 mg Tablet Sleeve (7mg Sleeve)

Packaging label for Teriflunomide Tablets 7 mg film-coated tablets by Biocon Pharma Inc. The label includes the NDC 70377-017-91, instructions for opening, prescription-only indication, and a 28-tablet count. It features the Biocon logo and dispensing instructions to provide the medication guide to each patient.*

FDA Label Image

Bottle-14mg (Bottle 14mg)

Label for Teriflunomide Tablets 14 mg, film-coated tablets for oral use, in a package containing 30 tablets. The label shows the Biocon Pharma Inc. logo and states the product is Rx Only. It includes dosage instructions, storage conditions, a barcode, and manufacturing details with locations in the USA and India.*

FDA Label Image

Carton-14mg (Teriflunomide 06)

Packaging label for Teriflunomide Tablets 14 mg oral film-coated tablets by Biocon Pharma Inc. The carton indicates 28 tablets per package and includes instructions for opening the blister card. It is labeled Rx only and notes the product is child-resistant, with storage instructions and manufacturer details from Biocon Pharma Inc. USA and Biocon Pharma Limited, India.*

FDA Label Image

Blister-14mg (Teriflunomide 07)

The packaging label for Teriflunomide Tablets shows the 14 mg strength in a film-coated tablet form. The box indicates the product is manufactured by Biocon Pharma Inc. and contains 28 tablets. The label includes dosage and storage instructions, a barcode, and the NDC 70377-018-91. The packaging features the Biocon logo and prescription-only status.*

FDA Label Image

14mg-sleeve (Teriflunomide 08)

The image shows the packaging label for Teriflunomide Tablets by Biocon Pharma Inc., featuring 14 mg strength film-coated tablets. The label includes instructions for tablet dispensing, a count of 28 tablets per package, and states the product is Rx only. The brand logo Biocon appears prominently at the bottom.*

FDA Label Image

Chemical Structure (Teriflunomide 01)

Chemical structure of teriflunomide, the active ingredient in the drug Teriflunomide. The structure includes a trifluoromethyl-substituted phenyl ring connected to an amide and carboxylic acid functional groups.*

FDA Label Image

Figure 1 (Teriflunomide 02)

Kaplan-Meier plot showing the percentage of disability progression sustained over 12 weeks in patients treated with placebo, 7 mg teriflunomide, and 14 mg teriflunomide. The x-axis represents the duration in weeks up to 108 weeks, while the y-axis shows the percentage of sustained disability progression. The graph includes a table of the number of patients at risk across time points for each group. Statistical significance is noted between 14 mg and placebo.*

FDA Label Image

Figure 2 (Teriflunomide 03)

A line graph showing disability progression sustained over 12 weeks in percentage on the y-axis and weeks on the x-axis up to 108 weeks. The graph compares three groups: Placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. It includes a number at risk table for each group at various time points below the x-axis. The 14 mg Teriflunomide group shows statistically significant lower disability progression compared to placebo (*p < 0.05).*

FDA Label Image

Principal Display Panel (7 mg Tablet Carton)

The packaging label for Teriflunomide Tablets 7 mg oral film-coated tablets by Biocon Pharma Inc. The carton indicates a 28-tablet count with the NDC 70377-017-91. Instructions for opening the blister card and storage conditions are also included on the label along with manufacturer details for Biocon Pharma Limited in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.